SciVision Biotech Inc.

Taiwan Stock Exchange 1786.TW

SciVision Biotech Inc. Price to Earnings Ratio (P/E) on January 14, 2025: 42.02

SciVision Biotech Inc. Price to Earnings Ratio (P/E) is 42.02 on January 14, 2025, a 43.67% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

SciVision Biotech Inc. 52-week high Price to Earnings Ratio (P/E) is 51.72 on August 20, 2024, which is 23.08% above the current Price to Earnings Ratio (P/E).
SciVision Biotech Inc. 52-week low Price to Earnings Ratio (P/E) is 28.31 on January 17, 2024, which is -32.64% below the current Price to Earnings Ratio (P/E).
SciVision Biotech Inc. average Price to Earnings Ratio (P/E) for the last 52 weeks is 39.87.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

Taiwan Stock Exchange: 1786.TW

SciVision Biotech Inc.

CEO	Tai Xian Han
IPO Date	March 12, 2013
Location	Taiwan
Headquarters	1, South 1st Road
Employees	64
Sector	Health Care
Industries Pharmaceuticals Chemicals & Advanced Materials Cosmetics

Description

SciVision Biotech Inc. manufactures and sells hyaluronic acid products in Taiwan. It offers synovial fluid supplements, facial dermal implants, absorbable adhesion barriers, and intravesical instillation products. The company was founded in 2001 and is based in Kaohsiung, Taiwan.

Key trends

Past 5 years